Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/14/2796136/0/en/Apellis-Provides-Update-on-Ongoing-Regulatory-Review-of-Pegcetacoplan-for-GA-in-the-European-Union.html

WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Read more at globenewswire.com

Related news for (APLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.